P2RX7 and amyotrophic lateral sclerosis: Proceeding from the initial recognition of the contribution of extracellular ATP to the neurodegeneration of the nervous system [10], to the encouraging results on the role of P2X7 in ALS [11,12], the present study aimed to provide a further translational opportunity in ALS by exploiting the therapeutic efficacy of new noncommercially available P2X7 antagonist AXX71 and AXX13 compounds.